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Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by memory loss and the
presence of amyloid plaques and neurofibrillary tangles in the patients’ brains. In this study, we investigated the
alterations in metabolite profiles of the hippocampal tissues from 6, 8, and 12 month-old wild-type (WT) and
5xfamiliar AD (5xFAD) mice, an AD mouse model harboring 5 early-onset familiar AD mutations, which shows
memory loss from approximately 5 months of age, by exploiting the untargeted metabolomics profiling. We found
that nicotinamide and adenosine monophosphate levels have been significantly decreased while
lysophosphatidylcholine (LysoPC) (16:0), LysoPC (18:0), and lysophosphatidylethanolamine (LysoPE) (16:0) levels have
been significantly increased in the hippocampi from 5xFAD mice at 8 months or 12 months of age, compared to
those from age-matched wild-type mice. In the present study, we focused on the role of nicotinamide and
examined if replenishment of nicotinamide exerts attenuating effects on the reduction in dendritic spine density in
hippocampal primary neurons from 5xFAD mice. Treatment with nicotinamide attenuated the deficits in spine
density in the hippocampal primary neurons derived from 5xFAD mice, indicating a potential role of nicotinamide
in the pathogenesis of AD. Taken together, these findings suggest that the decreased hippocampal nicotinamide
level could be linked with AD pathogenesis and be a useful therapeutic target for AD.
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Introduction
Alzheimer’s disease (AD) animal models have been used
to investigate pathogenic mechanisms, discover potential
biomarkers, and evaluate novel treatments [1, 2]. The
5xFAD mouse, a widely used AD mouse model, has 5 fa-
miliar AD-linked mutations, i.e., the Swedish (K670 N/
M671 L), Florida (I716V), and London (V717I) muta-
tions in amyloid precursor protein (APP) and the M146
L and L286 V mutations in presenilin-1 (PSEN1) [2].
5xFAD mice, characterized by cerebral amyloid plaques
and gliosis, show massive Aβ1–42 burdens from 2months
of age, declined synaptic markers from 4months of age,
and cognitive impairment from approximately 5 months
of age [2–5]. Thus, pathological mechanisms of AD
could be evaluated by analyzing biochemical changes in
the brain in 5xFAD mice at different disease stages.
Altered metabolites reflect downstream changes of
genomic, transcriptomic, and proteomic fluctuations,
and metabolomics data, such as an accurate biochemical
profile, can thus be used to visualize and interpret com-
plex biological networks of AD. Multiple human studies
have focused on metabolomics analysis of blood-derived
samples, cerebrospinal fluid, and postmortem brain tis-
sues, since, unlike for mouse models, premortem brain
samples are not available [6]. Targeted metabolomics of
44 postmortem brain samples showed that a panel of
sphingolipids is associated with the severity of AD
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pathology [7–9]. Arginine metabolism is altered in the post-
mortem hippocampus, superior frontal gyrus, and cerebel-
lum of AD patients and normal control subjects [10].
Brain metabolic perturbations have been described in
several transgenic AD models. For instance, the distur-
bances in metabolites of the glycolytic pathway (glucose-
6-phosphate and glycerol-3-phosphate) and tricarboxylic
acid (TCA) cycle (α-ketoglutarate, fumarate, and succin-
ate) were identified in astrocytes derived from newborn
5xFAD mice [11], and pantethine treatment reduced the
extent of metabolic perturbation and decreased the in-
flammatory processes in these astrocytes, indicating the
role of altered brain energetics in the AD pathogenesis;
metabolic profile analyses revealed region-specific meta-
bolic changes in the hippocampus, cortex, cerebellum,
and olfactory bulbs in APP/PS1 mice [12, 13], and meta-
bolomics signatures, including mitochondrial dysfunc-
tion and altered energy metabolism indicated by changes
in nucleotide, TCA cycle, energy transfer, neurotrans-
mitter, and amino acid metabolic pathways, were identi-
fied in APP/PS1 mice [14]; in addition, significant
changes in metabolite compositions, including accumu-
lation of fatty acids, alterations in phospholipids and
acylcarnitines related to neural membrane degradation,
and impaired energy management, were observed in the
hippocampus and cortex in APP/PS1 mice [13]. Because
the metabolic pathways are conserved through evolution
[15, 16], the metabolic signatures identified in AD
mouse models could be directly translated into human
studies [17]. Therefore, metabolomics screening in trans-
genic models could be useful for the understanding of
the pathological mechanisms of AD.
Amyloid β peptide (Aβ) deposition and neurofibrillary
tangles in the AD hippocampus, which is the central brain
region to exhibit neurodegeneration and other AD-related
alterations, possibly lead to cognitive impairment [18, 19].
In addition, hippocampal oxidative stress is implicated in
neurodegenerative diseases and neurodevelopmental dis-
orders [20, 21]. However, no study has investigated the
metabolomics profiling of the hippocampus in the 5xFAD
mouse model. This study aims to apply an untargeted
metabolomics approach to characterize metabolic abnor-




All experimental procedures were approved by the Ani-
mal Care Committee of Seoul National University (Ap-
proval Number: SNU-131016-1). Transgenic mice with 5
familial AD mutations were purchased from Jackson La-
boratories (strain: B6SJL-Tg [APPSwFlLon, PS1*M146
L*L286 V] 6799Vas/J) and were bred by crossing hemi-
zygous transgenic male mice with B6SJL F1 female mice.
Male WT and 5xFAD mice were used in all experiments.
Animal treatment and maintenance were performed in
accordance with the Institutional Animal Care and Use
Committee Guidelines of Seoul National University,
Seoul, Korea.
Chemicals and reagents
High-performance liquid chromatography grade sol-
vents, including methanol, acetonitrile, and water, were
purchased from J.T. Baker (PA, USA). Formic acid, nico-
tinamide, adenosine monophosphate, LysoPC, and
LysoPE were obtained from Sigma-Aldrich (MO, USA)
and Avanti Polar Lipids (AL, USA).
Hippocampus sample preparation for metabolomics
The hippocampus was weighed (~ 20 mg wet), homoge-
nized in methanol: water (4:1, v/v; 50 μl/mg tissue), and
frozen in liquid nitrogen for 1 min. The homogenate was
thawed at room temperature and was then sonicated for
5 s. After adding acetonitrile (30 μl/mg tissue), the hom-
ogenate was vortexed for 5 s incubated for 1 h at − 20 °C,
and centrifuged at 13,000 rpm for 15min at 4 °C. The
pellet was reconstituted in radioimmunoprecipitation
assay buffer (Elpis-Biotech, Daejeon, Korea), and the
concentration of total protein was determined using the
Pierce BCA Protein Assay Kit (Thermo Scientific, MA,
USA). The supernatant was transferred into a microcen-
trifuge tube and was dried under an N2 evaporator. The
dry extracts were then reconstituted with different vol-
umes of solvent mixtures (acetonitrile: H2O, 1:1, v/v)
based on the sample’s protein levels, and the mixtures
were sonicated for 10 min and centrifuged at 14,000 rpm
for 15min at 4 °C to remove insoluble debris. The super-
natant was used for the LC-MS analysis.
Untargeted metabolomics
A 4 μl aliquot of the sample was injected into a Waters
UPLC system with a reverse phase 2.1 × 100 mm
ACQUITY 1.8 μm HSS T3 column. The gradient mobile
phase comprised 0.1% formic acid (Solution A) and
methanol containing 0.1% formic acid (Solution B). Each
sample was resolved for 20 min at a flow rate of 0.4 ml/
min. The gradient consisted of 5% Solution B for 1 min,
5–30% Solution B over 1–8 min, 30–70% Solution B
over 8–13min, and 95% Solution B for 14 min (main-
taining for 2 min). The samples were equilibrated in 95%
Solution A for 3.5 min before injection. A Waters Xevo
G2 time-of-flight mass spectrometry was operated in
positive and negative ionization modes. To obtain con-
sistent differential variables, we prepared a pooled sam-
ple (quality control [QC] sample) by mixing aliquots of
individual samples. Replicates of the QC sample were ac-
quired in a series of injections, and data were obtained
by random injection. The metabolomic dataset was
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deconvoluted and peak aligned using Progenesis QI soft-
ware (version 2.3, Nonlinear Dynamics, Newcastle, UK).
The most suitable candidate QC sample was chosen by
the highest similarity using Progenesis QI software. Vector
alignment quality was manually processed, and files were
aligned with sensitivity (10 ppm), retention time limits,
and peak normalization (normalization to all compounds)
at the default values. Subsequently, ions with a % CV of
abundance > 30 in the QC were removed. A significantly
differential expression was defined as a false discovery rate
(FDR) adjusted p-value (q-value) < 0.05. The FDR was ob-
tained by adjusting the raw p-values of the t-test using the
method of Benjamini and Hochberg [22].
Hippocampal primary neuron culture
Hippocampal primary neurons, which were prepared
from postnatal day 1 to 2 5xFAD mice by dissociating
with 0.25% trypsin, were plated onto coverslips coated
with poly-L-lysine (Sigma, St Louis, USA). Neurons were
grown in Neurobasal medium (Gibco, CA, USA) supple-
mented with B27 (Gibco, CA, USA), 2 mM GlutaMAX-I
(Gibco, CA, USA), and 100 μg/ml penicillin/strepto-
mycin (Gibco, CA, USA) at 37 °C in a humidified envir-
onment of 95% O2/5% CO2.
Dendritic spine density analysis
Hippocampal primary neurons were transfected with
6 μg CAG-IRES-mGFP plasmid (a generous gift from Dr.
Kolodkin) in 18-mm glass coverslips in 60-mm dishes.
Nicotinamide (Sigma, St Louis, USA) was prepared in
saline. Neurons were treated with nicotinamide or ve-
hicle for 24 h. The number of dendritic spines was evalu-
ated at 18–19 days in vitro (DIV). Fluorescent images
were acquired using a confocal microscope (LSM 510;
Carl Zeiss, Jena, Germany) using the same setting condi-
tion for all samples. Spines were counted within the 20-
μm to 50-μm segments on secondary dendrites extend-
ing 50–100 μm beyond the soma.
Statistical analysis
One-way ANOVA and independent t-test (SPSS, IL, USA)
were used for determining the statistical significance. A
p < 0.05 or q < 0.05 was considered statistical significance.
Results
Hippocampus metabolic profiling
Untargeted metabolomics profiling of hippocampal tis-
sues was performed in WT and 5xFAD mice at three
different stages (6, 8, and 12months) (Fig. 1 a). The
number of WT and 5xFAD mice and the weights of hip-
pocampal tissues used are described in Table 1. In total,
2950 compound ions were identified in the positive ion
and negative ion electrospray ionization (ESI+ and ESI−,
respectively) modes. We selected ions with a q-value of
less than 0.05 in 5xFAD mice at each stage. Notably, 51
and 115 features were significantly different between
Fig. 1 Hippocampal metabolomics of 5xFAD mice at different disease progression stages. a Time course of the hippocampal sample collection. b
Venn diagram representing overlapping ion features that were significantly different between the hippocampi of WT and 5xFAD mice (q < 0.05)
at 6, 8, or 12 months of age. c Hierarchically clustered heat map of the relative intensity of 20 metabolic markers. Rows and columns represent
the individual mice and the 20 selected metabolites (retention time_m/z, *identified or putative metabolites), respectively. Each cell is colored
based on the relative intensity
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WT and 5xFAD mice at 8 and 12months of age, re-
spectively (Fig. 1b). No markers differed between WT
and 5xFAD mice at 6 months of age. Twenty ions that
were significantly different between WT and 5xFAD
mice at both 8 and 12months of age were selected for
further identification. The hierarchically clustered heat
map illustrates significant differences in the relative in-
tensity of the selected 20 markers (Fig. 1c). The selected
ions are described in Table 2. After removing the ion-
source fragment features, 5 metabolites were identified
as nicotinamide, adenosine monophosphate, LysoPC (16:
0), LysoPC (18:0), and LysoPE (16:0) by comparing the
MS/MS spectrum of each metabolite with that of the au-
thentic compound. The levels of nicotinamide and ad-
enosine monophosphate were significantly lower in
5xFAD mice than in WT mice (Fig. 2a and b), whereas
the levels of LysoPC (16:0), LysoPC (18:0), and LysoPE
(16:0) were significantly higher (q < 0.05) in 5xFAD mice
than in WT mice at 8 or 12months of age (Fig. 2c, d, and e).
Nicotinamide supplementation rescues the spine deficits in
hippocampal primary neurons derived from 5xFAD mice
Dendritic spine alteration is the cellular mechanism
underlying neuronal activity and memory. It has been re-
ported that treatment with nicotinamide rescues both
short- and long-term memory impairment in 3xTg-AD
mice, the triple-transgenic mice which harbor a knock-in
mutation of PSEN1M146V, the Swedish double mutation of
APPKM670/671NL, and a frontotemporal dementia mutation
in tau (tauP301L) on a 129/C57BL/6 background [23].
Dendritic spine density in hippocampal primary neu-
rons from 5xFAD mice was found to be significantly
lower than hippocampal primary neurons from WT
mice (WT + vehicle [n = 4], 5.84 ± 0.206 [spine number/
μm]; 5xFAD + vehicle [n = 3], 4.71 ± 0.160 [spine num-
ber/μm], p < 0.001) (Fig. 3a and b). Next, we examined
whether treatment with nicotinamide rescues the de-
crease in dendritic spine density in hippocampal primary
neurons cultured from 5xFAD mice. Treatment with 10
mM nicotinamide for 24 h rescued the reduction in den-
dritic spine density in hippocampal primary neurons at
17–18 DIV (5xFAD + vehicle [n = 3], 4.71 ± 0.160 [spine
number/μm]; 5xFAD + 10mM nicotinamide [n = 3],
5.52 ± 0.270 [spine number/μm], p < 0.05), while the
same treatment did not affect dendritic spine density of
WT hippocampal neurons (WT + vehicle [n = 4], 5.84 ±
0.206 [spine number/μm]; WT + 10mM nicotinamide
[n = 4], 5.93 ± 0.202 [spine number/μm]) (Fig. 3a and b).
These findings indicate that reduced dendritic spine
density in hippocampal primary neurons is, at least in
part, due to the decreased nicotinamide concentration in
the hippocampi from AD brains.
Discussion
AD is usually clinically diagnosed after its pathophysio-
logical process has already started. In the early AD stage,
Table 1 The number of male mice and tissue weights. The
mice were classified into 6 groups based on age (6, 8, and 12
months). HPC, hippocampus; SD, standard deviation
Age
(month)
Genotype HPC weight (mg) N
Mean ± SD
(min-max)
6 WT 20.5 ± 3.4 9
(15.0–25.6)
5xFAD 20.3 ± 5.4 9
(14.5–28.6)
8 WT 21.1 ± 2.7 6
(17.8–25.7)
5xFAD 24.4 ± 3.2 7
(20.4–29.2)
12 WT 19.7 ± 4.2 9
(10.0–24.9)
5xFAD 18.4 ± 2.8 8
(13.1–21.8)
Table 2 Hippocampal biomarkers that were significantly different (q < 0.05) both in 8 and 12 months
Metabolites Regulationa 8 M 12M Mass RT Ion
mode
Fragment ion (m/z)
q-value p-value q-value p-value (m/z) (min)
Nicotinamideb down 0.00161 0.00044 0.00161 0.00044 123.0554 0.97 POS 80.0502, 78.0339, 96.0439
LysoPC (16:0)b up 1.62E-05 1.52E-06 1.62E-05 1.52E-06 496.3402 12.14 POS 184.0735, 104.1076
LysoPC (18:0)b up 5.07E-07 1.09E-08 5.07E-07 1.09E-08 524.3719 12.61 POS 184.0739, 104.1074
Phosphatidic acidc up 2.01E-05 2.22E-06 2.01E-05 2.22E-06 487.2795 12.61 POS 445.2678
AMPa down 4.10E-06 8.02E-07 4.10E-06 8.02E-07 346.0545 0.97 NEG 96.9692, 134.0466, 150.9503
LysoPE (16:0)c up 1.67E-07 2.10E-08 1.67E-07 2.10E-08 452.2761 11.98 NEG 255.2324, 112.9855, 196.0417
LysoPE (16:0)a up 5.52E-08 5.39E-09 5.52E-08 5.39E-09 452.2772 12.1 NEG 255.2326, 122.9857, 196.0413
LysoPE (18:0)c up 1.37E-06 2.20E-07 1.37E-06 2.20E-07 480.3085 12.13 NEG 255.2322
aUp- or down- regulation in 5xFAD vs. WT. b identified metabolite compared with authentic standard. cputative metabolites compared with database. RT Retention
time, CE Colision energy
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patients show mild cognitive impairment, which de-
velops into AD in the rate of approximately 15% per year
[24, 25]. Therefore, the understanding of molecular
pathogenesis in the pre-clinical process is essential for
identifying treatment targets.
While there are some reports that have determined
the metabolomics profiles associated with the progres-
sion of AD using postmortem brain tissues and blood
samples [7, 26, 27], we are the first to address alterations
in brain metabolism associated with AD in the hippo-
campus of 5xFAD mice in three different disease stages.
Nicotinamide, an amide form of vitamin B3, is the pri-
mary precursor of nicotinamide adenine dinucleotide
(NAD+) in mammalian cells [28, 29]. Nicotinamide is
converted to NAD+ through the activity of nicotinamide
phosphoribosyltransferase, a rate-limiting enzyme in
NAD+ biosynthesis. As an energy substrate and cofactor
for many enzymes, NAD+ is critical for mitochondrial
health and neuronal stress resistance [30, 31]. NAD+ is a
crucial cofactor for cellular processes, such as glycolysis,
fatty acid β-oxidation, tricarboxylic acid cycle, and DNA
repair [32, 33]. NAD+-dependent signaling, which is asso-
ciated with neuronal development, survival, and function
in the central nervous system, is implicated in neuropro-
tection [34]. The potential role of nicotinamide in AD has
been highlighted in several studies. For instance, oral
treatment with nicotinamide improves cognitive perform-
ance and reduces Aβ and hyperphosphorylated tau path-
ologies in 3xTg-AD mice [34], and nicotinamide preserves
cellular NAD+ levels and increases the resistance of
Fig. 2 Relative abundance of metabolites in the hippocampus in 5xFAD mice at each age. a nicotinamide, b AMP, c LysoPC (16:0), d LysoPC
(18:0), and e LysoPE (16:0). Data are shown as means ± SEM of at least 3 independent experiments; 6 M-WT (n = 9), 6 M-5xFAD (n = 9), 8 M-WT
(n = 6), 8 M-5xFAD (n = 7), 12 M-WT (n = 9), and 12 M-5xFAD (n = 8). *q < 0.05 compared with age-matched WT mice. AMP, adenosine
monophosphate; LysoPC, lysophosphatidylcholine; LysoPE, lysophosphatidylethanolamine
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neurons against excitotoxicity [35]. The findings indicate
the neuroprotective effect of nicotinamide and NAD+.
However, no study has investigated the alterations of nico-
tinamide in the brain of AD models or patients. Although
many reports have demonstrated the potential role of
nicotinamide in neuroprotection and cognition, how the
nicotinamide level changes in AD is not known. Here, we
report novel findings that nicotinamide levels are de-
creased in the hippocampus of 5xFAD mice. This finding
supports the hypothesis that NAD + -dependent signaling
is disturbed in the AD brain.
In this study, we have investigated whether the supple-
mentation of nicotinamide attenuates the reduction in
dendritic spine density using cultured primary neurons
from the hippocampus of 5XFAD mice (Fig. 3). Recent
evidence has strongly indicated that cultured neurons
from AD mouse models represent valuable models of
this neurodegenerative disorder. Neurons derived from
Tg2576 mice, a mouse model carrying a single mutation
in human APP, show high intensity staining for the hu-
man APP protein/Aβ fragments and increased vulner-
ability [36]. Additionally, the total number of dendritic
spines, total spine extent, spine surface area, spine head
diameter, and spine cross-sectional area are significantly
decreased in neurons from APP/PS1 mice, a mouse
model carrying double AD-associated mutations [37].
Fig. 3 Nicotinamide treatment rescues synaptic loss in hippocampal primary neurons derived from 5xFAD mice. a Representative images of
dendritic spines in primary WT and 5xFAD hippocampal neurons at 18–19 DIV. The dendritic segment outlined with a white box (upper) is
magnified to delineate the spine morphology (bottom) with a 3× optic zoom. The scale bars indicate 20 μm and 10 μm in the low- and high-
magnification images, respectively. b Quantification of the spine densities. The dendritic spine densities were significantly reduced in neurons
derived from 5xFAD mice (n = 28 neurons, one-way ANOVA) compared with those from WT mice (n = 39 neurons). Treatment with nicotinamide
significantly attenuated the reduction in dendritic spine density in primary hippocampal neurons derived from 5xFAD mice (n = 17 neurons, one-
way ANOVA). Data are represented as mean ± SEM. *p < 0.05, ***p < 0.001 compared with mGFP-transfected WT hippocampal primary neurons;
#p < 0.001 compared with mGFP-transfected 5xFAD hippocampal primary neurons. NA, nicotinamide; DIV, days in vitro
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Synaptic loss is one of the pathological hallmarks of AD
and best correlates with cognitive decline, suggesting
that it is a critical event in the pathophysiology of the
disease [38]. Based on these previous reports, it can be
said that cultured neurons from AD animal model re-
flect AD phenotypes in vitro and can be used in AD
study. Thus, we assumed that the primary neurons from
5xFAD reflect the hippocampal pathophysiological char-
acteristics of 5xFAD and treated nicotinamide to the pri-
mary neurons. Treatment with nicotinamide rescued
synaptic deficits in hippocampal primary neurons de-
rived from 5xFAD mice (Fig. 3). Together with those in
the study by Liu et al. [34], our findings indicate that
nicotinamide is a potential therapeutic drug for AD.
However, further studies are needed to investigate
whether nicotinamide supplementation improves cogni-
tion in 5xFAD mice.
Reduced adenosine monophosphate levels have signifi-
cant consequences, such as impairments in cellular en-
ergy homeostasis, because adenosine monophosphate
plays a central role in glucose and lipid metabolism
through the adenosine monophosphate-activated protein
kinase, which is known to be decreased in AD brains
[39, 40]. In addition, significantly decreased adenosine
monophosphate levels were detected in the hippocam-
pus and cortex of APP/PS1 mice [13]. Notably, elevated
adenosine monophosphate deaminase activity, which has
been identified in the postmortem brain in AD patients,
might lead to degradation of adenosine monophosphate
and over-production of ammonia [41].
Fig. 4 A graphical summary of this study, i.e. the reduction in nicotinamide in the hippocampus from 5xFAD mice as evaluated with untargeted
metabolomics profiling, and the effect of supplementation on dendritic spine density of hippocampal primary neuron cultures from 5xFAD mice.
5xFAD mice displayed decreased content of nicotinamide and AMP, and increased content of LysoPC (16:0), LysoPC (18:0), LysoPE (16:0) in the
hippocampus age-dependently. The addition of nicotinamide to hippocampal primary neuron culture from 5xFAD mice restored the reduced
dendritic spine density. These results suggest nicotinamide as a therapeutic target in AD
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We found that lysoPC and lysoPE levels increased in
the hippocampus in 5xFAD mice. Phospholipids, includ-
ing lysoPC and lysoPE, are metabolized by phospholip-
ase A2 (PLA2) from PC and PE, respectively [42]. PLA2
activity has been shown to vary in different AD stages.
In the early AD stage, PLA2 activity is decreased in the
brains of AD patients [43, 44]. However, as the disease
advances, PLA2 activity is elevated in AD brains [45]. In-
creased activation of PLA2 might induce an inflamma-
tory condition by activating the arachidonic acid
cascade, which plays a vital role in the inflammatory
process. Furthermore, it has been demonstrated that
LysoPC induces the formation of oligomer Aβ and sub-
sequent neurodegeneration in cultured neuronal cells
[46]. Therefore, increased phospholipid levels might be
associated with elevated PLA2 activity and increased in-
flammation in AD brains.
Conclusion
This study is the first to investigate hippocampal meta-
bolic markers in 5xFAD mice using an untargeted meta-
bolomics approach. Another important aspect of this
work is the comprehensive analysis across different dis-
ease progression stages. As summarized in the graphical
summary of Fig. 4, we found decreased nicotinamide
and adenosine monophosphate levels and increased
LysoPC (16:0), LysoPC (18:0), and LysoPE (16:0) levels
in the hippocampi in 5xFAD mice at 8 or 12 months of
age. We also demonstrated that nicotinamide rescued
the synaptic deficits of 5xFAD hippocampal primary
neurons. This study is the first to demonstrate the re-
duced hippocampal nicotinamide levels in 5xFAD mice,
and the findings suggest that the hippocampal nicotina-
mide level could be a useful therapeutic target for AD.
Further studies are needed to clarify the metabolic path-
way of nicotinamide and the molecular mechanism
underlying altered nicotinamide levels in the hippocam-
pus of 5xFAD mice.
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